Evidence map›Paper›PMID 32101751›Full record

ArticleCell reports2020

TIFAB Regulates USP15-Mediated p53 Signaling during Stressed and Malignant Hematopoiesis.

Madeline Niederkorn, Kathleen Hueneman, Kwangmin Choi, Melinda E Varney, Laurel Romano, Mario A Pujato, Kenneth D Greis, Jun-Ichiro Inoue, Ruhikanta Meetei, Daniel T Starczynowski

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. The roles of ubiquitination in AML.Annals of hematology · 2024
    Review
  10. TIFAB regulates the TIFA-TRAF6 signaling pathway involved in innate immunity by forming a heterodimer complex with TIFA.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  11. Article
  12. Review
  13. Article
  14. International journal of molecular sciences · 2023
    Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Madeline NiederkornDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA; Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45267, USA.
Kathleen HuenemanDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Kwangmin ChoiDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Melinda E VarneyDepartment of Pharmaceutical Science and Research, Marshall University, Huntington, WV 25701, USA.
Laurel RomanoDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA; Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45267, USA.
Mario A PujatoCenter for Autoimmune Genetics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA; Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, 45229, USA.
Kenneth D GreisDepartment of Cancer Biology, University of Cincinnati, Cincinnati, OH 45267, USA.
Jun-Ichiro InoueDivision of Cellular and Molecular Biology, The Institute of Medical Science, the University of Tokyo, Tokyo 108-8639, Japan.
Ruhikanta MeeteiDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Daniel T StarczynowskiDivision of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA; Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45267, USA; Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. Electronic address: daniel.starczynowski@cchmc.org.
Cincinnati Children's Hospital Medical Center · USUniversity of Cincinnati · USMarshall University · USThe University of Tokyo · JP

Funding

Training Program in Cancer TherapeuticsT32CA117846 · NCI · UNIVERSITY OF CINCINNATI · PI PRICE, CAROLYN M, TAKIAR, VINITA · 2006 to 2022
$6.5M
Decoding innate immune signaling in normal and myelodysplastic hematopoiesisR35HL135787 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI STARCZYNOWSKI, DANIEL · 2017 to 2022
$4.6M
Targeting IRAK1/4 in Myelodysplastic SyndromesR01DK113639 · NIDDK · CINCINNATI CHILDRENS HOSP MED CTR · PI STARCZYNOWSKI, DANIEL · 2017 to 2020
$1.9M
Enhanced proteomics capabilities for quantitation of proteins with a triple quadS10RR027015 · NCRR · UNIVERSITY OF CINCINNATI · PI GREIS, KENNETH DONALD · 2010 to 2010
$426k
Regulators of ubiquitin signaling in malignant hematopoiesisF99CA234924 · NCI · UNIVERSITY OF CINCINNATI · PI NIEDERKORN, MADELINE · 2018 to 2019
$76k
The TIFAB-USP15 Complex in the Pathogenesis of MDS and AMLF31HL137310 · NHLBI · UNIVERSITY OF CINCINNATI · PI NIEDERKORN, MADELINE · 2018 to 2018
$8k
NCI NIH HHS F99 CA234924NCI NIH HHS T32 CA117846NCRR NIH HHS S10 RR027015NHLBI NIH HHS F31 HL137310NHLBI NIH HHS R35 HL135787NIDDK NIH HHS R01 DK113639
6 · The paper itself

Abstract

TRAF-interacting protein with a forkhead-associated domain B (TIFAB) is implicated in myeloid malignancies with deletion of chromosome 5q. Employing a combination of proteomic and genetic approaches, we find that TIFAB regulates ubiquitin-specific peptidase 15 (USP15) ubiquitin hydrolase activity. Expression of TIFAB in hematopoietic stem/progenitor cells (HSPCs) permits USP15 signaling to substrates, including MDM2 and KEAP1, and mitigates p53 expression. Consequently, TIFAB-deficient HSPCs exhibit compromised USP15 signaling and are sensitized to hematopoietic stress by derepression of p53. In MLL-AF9 leukemia, deletion of TIFAB increases p53 signaling and correspondingly decreases leukemic cell function and development of leukemia. Restoring USP15 expression partially rescues the function of TIFAB-deficient MLL-AF9 cells. Conversely, elevated TIFAB represses p53, increases leukemic progenitor function, and correlates with MLL gene expression programs in leukemia patients. Our studies uncover a function of TIFAB as an effector of USP15 activity and rheostat of p53 signaling in stressed and malignant HSPCs.

Indexed as

HematopoiesisSignal TransductionAnimalsCatalytic DomainCell Line, TumorDisease Models, AnimalHEK293 CellsHematopoietic Stem CellsHumansIntracellular Signaling Peptides and ProteinsLeukemia, Myeloid, AcuteMiceMyeloid-Lymphoid Leukemia ProteinProtein BindingStress, PhysiologicalTumor Suppressor Protein p53Intracellular Signaling Peptides and ProteinsMyeloid-Lymphoid Leukemia ProteinTifab protein, humanTumor Suppressor Protein p53UbiquitinUbiquitin-Specific ProteasesUSP15 protein, humanAMLDUBhematopoiesisp53TIFATIFABTRAF6USP15

Identifiers

PMID32101751
PMCPMC7384867
OpenAlexW3008430386

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.